Your browser doesn't support javascript.
loading
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.
Brown, Janet E; Royle, Kara-Louise; Gregory, Walter; Ralph, Christy; Maraveyas, Anthony; Din, Omar; Eisen, Timothy; Nathan, Paul; Powles, Tom; Griffiths, Richard; Jones, Robert; Vasudev, Naveen; Wheater, Matthew; Hamid, Abdel; Waddell, Tom; McMenemin, Rhona; Patel, Poulam; Larkin, James; Faust, Guy; Martin, Adam; Swain, Jayne; Bestall, Janine; McCabe, Christopher; Meads, David; Goh, Vicky; Min Wah, Tze; Brown, Julia; Hewison, Jenny; Selby, Peter; Collinson, Fiona.
Affiliation
  • Brown JE; Department of Oncology and Metabolism, University of Sheffield, Weston Park Hospital, Sheffield. Electronic address: j.e.brown@sheffield.ac.uk.
  • Royle KL; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • Gregory W; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • Ralph C; Leeds Institute of Medical Research at St James's, Leeds Institute for Medical Research, University of Leeds, Leeds, UK.
  • Maraveyas A; Queens Centre for Oncology and Haematology, Faculty of Health Sciences, Hull York Medical School, Hull, UK.
  • Din O; Department of Clinical Oncology, Cancer Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
  • Eisen T; Department of Oncology, University of Cambridge, Cambridge, UK; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Nathan P; Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust, Northwood, UK.
  • Powles T; Barts Cancer Institute, Queen Mary University, London, UK.
  • Griffiths R; The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK.
  • Jones R; University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK.
  • Vasudev N; Leeds Institute of Medical Research at St James's, Leeds Institute for Medical Research, University of Leeds, Leeds, UK.
  • Wheater M; University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • Hamid A; Broomfield Hospital, Mid and South Essex NHS Foundation Trust, Chelmsford, UK.
  • Waddell T; Christie NHS Foundation Trust, Manchester, UK.
  • McMenemin R; Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK.
  • Patel P; Academic Unit of Translational Medical Sciences, University of Nottingham, Nottingham, UK.
  • Larkin J; Royal Marsden NHS Foundation Trust, London, UK.
  • Faust G; Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust, Leicester, UK.
  • Martin A; Academic Unit of Health Economics, Leeds Institute for Medical Research, University of Leeds, Leeds, UK.
  • Swain J; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • Bestall J; Leeds Institute of Health Sciences, Leeds Institute for Medical Research, University of Leeds, Leeds, UK.
  • McCabe C; Centre for Public Health, Queens University, Belfast, UK.
  • Meads D; Academic Unit of Health Economics, Leeds Institute for Medical Research, University of Leeds, Leeds, UK.
  • Goh V; School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.
  • Min Wah T; Department of Radiology, Leeds Institute for Medical Research, University of Leeds, Leeds, UK.
  • Brown J; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • Hewison J; Leeds Institute of Health Sciences, Leeds Institute for Medical Research, University of Leeds, Leeds, UK.
  • Selby P; Leeds Institute of Medical Research at St James's, Leeds Institute for Medical Research, University of Leeds, Leeds, UK.
  • Collinson F; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
Lancet Oncol ; 24(3): 213-227, 2023 03.
Article in En | MEDLINE | ID: mdl-36796394
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell Type of study: Clinical_trials / Guideline / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Female / Humans / Male Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2023 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell Type of study: Clinical_trials / Guideline / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Female / Humans / Male Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2023 Type: Article